Search results
Results from the WOW.Com Content Network
Spironolactone is commonly used in the treatment of hirsutism in women, and is considered to be a first-line antiandrogen for this indication. [68] Spironolactone can be used in the treatment of female-pattern hair loss (pattern scalp hair loss in women). [69] There is tentative low quality evidence supporting its use for this indication. [70]
Spironolactone has been identified as an inhibitor of NRG1‐ERBB4 signaling. [142] Spironolactone has been found to act as a potent inhibitor of the pannexin 1 channel, and this action appears to be involved in its antihypertensive effects independently of MR antagonism. [143] Spironolactone has been found to block hERG channels. [144]
[152] [148] [161] For these reasons, bicalutamide has replaced spironolactone in the treatment of the condition. [100]: 2139 For comparison to bicalutamide, a higher dosage of spironolactone of 5 mg/kg (or about 100 to 150 mg in boys that are 20 to 30 kg or 45 to 65 lbs) once daily is recommended for use in male peripheral precocious puberty.
The trial was stopped early because the beneficial effect of spironolactone on all-cause death exceeded the prespecified discontinuation requirements. Spironolactone reduced the risk of death by 30% compared to placebo. Additionally, there was a 35% reduction in the risk of hospitalization for worsening heart failure in the spironolactone group.
Canrenone is an active metabolite of spironolactone, canrenoic acid, and potassium canrenoate, and is considered to be partially responsible for their effects. [9] It has been found to have approximately 10 to 25% of the potassium-sparing diuretic effect of spironolactone, [ 16 ] whereas another metabolite, 7α-thiomethylspironolactone (7α-TMS ...
Like spironolactone, it is a prodrug, and is metabolized to active canrenone in the body. [ 3 ] [ 4 ] Potassium canrenoate is notable in that it is the only clinically used antimineralocorticoid which is available for parenteral administration (specifically intravenous ) [ 4 ] [ 5 ] as opposed to oral administration .
Osilodrostat's safety and effectiveness for treating Cushing's disease among adults was evaluated in a study of 137 adult subjects (about three-quarters women) with a mean age of 41 years. [3] The majority of subjects either had undergone pituitary surgery that did not cure Cushing's disease or were not surgical candidates. [3]
Hyperkalemia may occur; people who are also taking spironolactone or eplerenone may be at higher risk. [3] Anemia may occur, due to inhibition of the renin–angiotensin system. [20] As with other angiotensin receptor blockers, candesartan can rarely cause severe liver injury. [21] Candesartan cilexetil